Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSPC Pharmaceutical Group ( (HK:1093) ) has shared an update.
CSPC Pharmaceutical Group has announced ongoing negotiations for three potential license and collaboration transactions aimed at the development and commercialization of its pharmaceutical products, including EGFR-ADC. These transactions could bring in approximately US$5 billion in aggregate payments, with one deal expected to be finalized by June 2025, potentially impacting the company’s market positioning and financial outlook.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$6.21 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a Hong Kong-based company involved in the pharmaceutical industry, focusing on the development, manufacturing, and commercialization of pharmaceutical products. The company is known for its technology platforms and products such as epidermal growth factor receptor antibody drug conjugate (EGFR-ADC).
Average Trading Volume: 154,501,034
Technical Sentiment Signal: Buy
Current Market Cap: HK$79.34B
See more data about 1093 stock on TipRanks’ Stock Analysis page.